Aposense Ltd. (TASE: APOS) has signed a collaboration agreement with Roche Holding AG (SWX: RL). Under the agreement, Roche will use Aposense's EarliTest solution, in Roche's oncology development program.
EarliTest is designed to image tumor response at an early stage during treatment and has the potential to accelerate drug development by providing feedback on the biological effect of treatment. Data generated from the collaboration will provide an opportunity for the parties to expand utility of EarliTest to novel oncology therapies.
Aposense CEO Yoram Ashery said, "This collaboration with Roche, an industry leader in the field of oncology, demonstrates the interest within the pharmaceutical industry in using novel tools for early assessment of response to anticancer treatment in clinical trials. The delayed availability of feedback on drug activity using traditional methods is a significant unmet need, not only for patients, but also in the development of novel therapies for combating cancer."
According to the terms of the non-exclusive agreement, Roche will fund the clinical trials and pay Aposense undisclosed license and milestone fees.
Aposense has previously signed a similar non exclusive major agreement with GlaxoSmithKline plc (NYSE; LSE: GSK), which bought the company's imaging device for testing the effectiveness of cancer drugs.